This grant, offered by a leading health research agency, is for optimizing advanced genome editing therapeutics targeting Alzheimer’s Disease and related dementias (AD/ADRD). It supports the development of promising therapeutic leads, advancing them towards crucial Investigational New Drug (IND)-enabling studies. Applicants must demonstrate strong proof-of-concept in relevant models. The aim is to optimize candidates showing excellent bioactivity, manufacturability, biodistribution, and in vivo efficacy, alongside optimal dosing. This funding broadly addresses the AD/ADRD spectrum, encompassing Frontotemporal dementia, Lewy body dementias, Vascular contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias, aiming for impactful preclinical therapeutic advancements.
Opportunity ID: 343237
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-23-017 |
| Funding Opportunity Title: | Optimization of Genome Editing Therapeutics for Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) (U01 – Clinical Trials Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 24, 2022 |
| Last Updated Date: | Aug 24, 2022 |
| Original Closing Date for Applications: | Nov 30, 2022 |
| Current Closing Date for Applications: | Nov 30, 2022 |
| Archive Date: | Jan 05, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $650,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education Public housing authorities/Indian housing authorities County governments Native American tribal governments (Federally recognized) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Special district governments For profit organizations other than small businesses State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This FOA is not specific for any one or group within the AD/ADRD spectrum of disorders. Disorders, and includes genome editing therapies for: Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), Alzheimers Disease (AD) and Multiples Etiology Dementias (MED). |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-017.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00276544 | Oct 30, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277993 | Nov 04, 2022 | Nov 30, 2022 | View |
Package 1
Mandatory forms
343237 RR_SF424_5_0-5.0.pdf
343237 PHS398_CoverPageSupplement_5_0-5.0.pdf
343237 RR_OtherProjectInfo_1_4-1.4.pdf
343237 PerformanceSite_4_0-4.0.pdf
343237 RR_KeyPersonExpanded_4_0-4.0.pdf
343237 PHS398_ResearchPlan_4_0-4.0.pdf
343237 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343237 RR_Budget_3_0-3.0.pdf
343237 RR_SubawardBudget30_3_0-3.0.pdf
343237 PHS398_ModularBudget_1_2-1.2.pdf
343237 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
343237 RR_SF424_5_0-5.0.pdf
343237 PHS398_CoverPageSupplement_5_0-5.0.pdf
343237 RR_OtherProjectInfo_1_4-1.4.pdf
343237 PerformanceSite_4_0-4.0.pdf
343237 RR_KeyPersonExpanded_4_0-4.0.pdf
343237 PHS398_ResearchPlan_5_0-5.0.pdf
343237 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343237 RR_Budget_3_0-3.0.pdf
343237 RR_SubawardBudget30_3_0-3.0.pdf
343237 PHS398_ModularBudget_1_2-1.2.pdf
343237 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
